US 11,738,023 B2
Treatment and prevention of sleep disorders
Stephen C. Harris, Weston, CT (US); Ram P. Kapil, Princeton Junction, NJ (US); Donald J. Kyle, Yardley, PA (US); and Garth Whiteside, Yardley, PA (US)
Assigned to Purdue Pharma L.P., Stamford, CT (US)
Filed by Purdue Pharma L.P., Stamford, CT (US)
Filed on Mar. 8, 2021, as Appl. No. 17/195,434.
Application 17/195,434 is a continuation of application No. 16/318,686, granted, now 10,974,081, previously published as PCT/IB2017/054506, filed on Jul. 25, 2017.
Claims priority of provisional application 62/536,097, filed on Jul. 24, 2017.
Claims priority of provisional application 62/366,960, filed on Jul. 26, 2016.
Prior Publication US 2021/0330994 A1, Oct. 28, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/498 (2006.01); A61P 25/20 (2006.01); A61M 21/00 (2006.01)
CPC A61K 31/498 (2013.01) [A61P 25/20 (2018.01); A61M 21/00 (2013.01)] 20 Claims
 
1. A method for treating a sleep disorder, comprising administering to a human patient in need thereof from about 0.05 mg to about 100 mg of a compound of Formula (1)

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.